topic

625 Bispecific personalized aptamer for the treatment of solid tumors
Erez Lavi, Nir Skalka, Neta Zilony Hanin, Zohar Pode, Anastasia Paz, Yeela Scharff, Neria Reiss, Omer Levy, Elinor Debby, Liron Levy- Efrati, Vitaliy Buravenkov, Itay Liron, Yaniv Amir, Raanan Berger, Ido Bachelet, Guy Neev, Irit Carmi Levy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A375-A376; DOI: 10.1136/jitc-2020-SITC2020.0625
627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer
Keegan Cooke, Juan Estrada, Jinghui Zhan, Jonathan Werner, Fei Lee, Aditya Shetty, Marie-Anne Damiette Smit, Mark Salvati, Julie Bailis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A376-A377; DOI: 10.1136/jitc-2020-SITC2020.0627
629 Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody
Emily Hsiue, Katharine Wright, Jacqueline Douglass, Michael Hwang, Brian Mog, Alexander Pearlman, Annika Schaefer, P Aitana Azurmendi, Qing Wang, Drew Pardoll, Nickolas Papadopoulos, Kenneth Kinzler, Bert Vogelstein, Sandra Gabelli, Shibin Zhou

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A377-A378; DOI: 10.1136/jitc-2020-SITC2020.0629
630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models
Seema Kantak, Bryan Glaser, Justin Wetter, Bee-Cheng Sim, Jeff Higaki, Jacob Beal, Sara Ollerman, Dileep Pulukkunat, Mandar Bawadekar, Charles Kaplan, Peter Lamb, Bonnie Hammer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A378; DOI: 10.1136/jitc-2020-SITC2020.0630
633 Dual-targeting of 4–1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor
Michelle Nelson, Robert Miller, Gabriele Blahnik-Fagan, Lauren Loh, Danielle Van Citters, Lynda Misher, Megan Sprague, Maria Dasovich, Irene Barber, Kathy Maggiora, Franz Gruswitz, Brian Woodruff, Kelsey Huntington, Aelish Guinn, Megan Aguilar, Mollie Daugherty, Elizabeth Haglin, Jane Gross, Peter Pavlik, Catherine McMahan, David Bienvenue, Gabriela Hernandez-Hoyos

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A379-A380; DOI: 10.1136/jitc-2020-SITC2020.0633
60 Development and validation of blood tumor mutational burden reference standards
Eun-Ang Rabier-Moreau, Guillem Portella, Matthew Butler, Yves Konigshofer, James Hadfield

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A38; DOI: 10.1136/jitc-2020-SITC2020.0060
635 A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders
Christian Vidal, Michael Cukan, Rajat Varma, Lawrence Iben, Tanya Berbasova, Ada Vaill, Anna Bunin, Ann Marie Rossi, David Trinh, Katy McGrath, Enrique Alvarez, Matthew Welsch, Luca Rastelli

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A380; DOI: 10.1136/jitc-2020-SITC2020.0635
639 Immune-related thyroid dysfunction in patients with existing thyroid dysfunction
Francois Kaleta, Heather Brody, Praveen Namireddy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A382-A383; DOI: 10.1136/jitc-2020-SITC2020.0639
638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
Noha Abdel-Wahab, Adi Diab, Hiroyuki Katayama, Sang Kim, Samir Hanash, Maria Suarez-Almazor

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A382; DOI: 10.1136/jitc-2020-SITC2020.0638
640 Characterizing severe acute kidney injury in patients treated with immune checkpoint inhibitors
Chung-Jiah Chen, Lisa Kim, Ashley Weaver, Sandip Patel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A383-A384; DOI: 10.1136/jitc-2020-SITC2020.0640

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages